Renaissance Technologies LLC lifted its holdings in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 26.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,783,100 shares of the medical research company’s stock after acquiring an additional 378,176 shares during the period. Renaissance Technologies LLC’s holdings in Genomic Health were worth $125,209,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Globeflex Capital L P bought a new stake in shares of Genomic Health during the second quarter worth about $116,000. Sun Life Financial INC purchased a new position in Genomic Health during the second quarter worth about $122,000. Trexquant Investment LP purchased a new position in Genomic Health during the third quarter worth about $202,000. SG Americas Securities LLC purchased a new position in Genomic Health during the second quarter worth about $162,000. Finally, D.A. Davidson & CO. purchased a new position in Genomic Health during the third quarter worth about $234,000. 89.21% of the stock is owned by institutional investors.
Genomic Health stock opened at $72.90 on Friday. Genomic Health, Inc. has a fifty-two week low of $26.54 and a fifty-two week high of $92.18. The stock has a market cap of $2.73 billion, a P/E ratio of 92.07 and a beta of 0.40.
Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, November 6th. The medical research company reported $0.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.28. The firm had revenue of $101.30 million for the quarter, compared to analysts’ expectations of $94.27 million. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) earnings per share. As a group, analysts predict that Genomic Health, Inc. will post 1.06 EPS for the current year.
GHDX has been the topic of several analyst reports. Zacks Investment Research cut shares of Genomic Health from a “buy” rating to a “hold” rating in a report on Wednesday, September 5th. Raymond James initiated coverage on shares of Genomic Health in a report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Canaccord Genuity restated a “buy” rating and set a $82.00 price target (up from $70.00) on shares of Genomic Health in a report on Wednesday, November 7th. Finally, BidaskClub upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 30th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $48.33.
In other Genomic Health news, insider Steven Shak sold 5,500 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $63.05, for a total value of $346,775.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider James J. Vaughn sold 3,000 shares of the business’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $85.18, for a total transaction of $255,540.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,635,985 shares of company stock worth $126,469,701. Corporate insiders own 45.80% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/12/08/renaissance-technologies-llc-acquires-378176-shares-of-genomic-health-inc-ghdx.html.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Recommended Story: Buyback For Investors Defined
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.